Oleic Acid-13C5 (Synonyms: 9Z-Octadecenoic Acid-13C5, C18:1(9Z)-13C5, cis-9-Octadecenoic Acid-13C5) |
| Katalog-Nr.GC52318 |
An internal standard for the quantification of oleic acid
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1255644-48-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Oleic acid-13C5 is intended for use as an internal standard for the quantification of oleic acid by GC- or LC-MS. Oleic acid is a monounsaturated fatty acid and a major component of membrane phospholipids that has been found in human plasma, cell membranes, and adipose tissue.1,2 It contributes approximately 17% of the total fatty acids esterified to phosphatidylcholine, the major phospholipid class in porcine platelets.1 Oleic acid inhibits collagen-stimulated platelet aggregation by approximately 90% when used at a concentration of 10 µg/ml. It also inhibits fMLF-induced neutrophil aggregation and degranulation by 55 and 68%, respectively, when used at a concentration of 5 µM, similar to arachidonic acid .3 Oleic acid (60 µM) induces release of intracellular calcium in human platelets.4 In vivo, oleic acid increases TNF-α, IL-8, IL-6, and IL-1β production, neutrophil accumulation, and apoptotic and necrotic cell death in mouse lung and has been used to induce lung injury in a mouse model of acute respiratory distress syndrome (ARDS).2
1.Wahle, K.W., and Peacock, L.I.Effects of isomeric cis and trans eighteen carbon monounsaturated fatty acids on porcine platelet functionBiochim. Biophys. Acta1301(1-2)141-149(1996) 2.GonÇalves-de-Albuquerque, C.F., Silva, A.R., Burth, P., et al.Acute respiratory distress syndrome: Role of oleic acid-triggered lung injury and inflammationMediators Inflamm.260465(2015) 3.Naccache, P.H., Moiski, T.F., Volpi, M., et al.Modulation of rabbit neutrophil aggregation and degranulation by free fatty acidsJ. Leukoc. Biol.36(3)333-340(1984) 4.Siafaka-Kapadai, A., Hanahan, D.J., and Javors, M.A.Oleic acid-induced Ca2+ mobilization in human platelets: Is oleic acid an intracellular messenger•J. Lipid Mediat. Cell Signal15(3)215-232(1997)
| Cas No. | 1255644-48-4 | SDF | |
| Überlieferungen | 9Z-Octadecenoic Acid-13C5, C18:1(9Z)-13C5, cis-9-Octadecenoic Acid-13C5 | ||
| Canonical SMILES | CCCCCCCC/C=C\[13CH2][13CH2]CCC[13CH2][13CH2][13C](O)=O | ||
| Formula | C13[13C]5H34O2 | M.Wt | 287.4 |
| Löslichkeit | Chloroform: soluble,DMF: >100mg/mL,DMSO: >100mg/mL,Ethanol: >100mg/mL,PBS (pH 7.2): <100ug/mL | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4795 mL | 17.3974 mL | 34.7947 mL |
| 5 mM | 0.6959 mL | 3.4795 mL | 6.9589 mL |
| 10 mM | 0.3479 mL | 1.7397 mL | 3.4795 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *